Actemra gca?

Actemra for Giant Cell Arteritis (GCA)

Actemra, a medication developed by Roche, is an interleukin-6 (IL-6) receptor antagonist. It is used to treat various inflammatory conditions, including Giant Cell Arteritis (GCA) [1].

What is Giant Cell Arteritis (GCA)?

GCA, also known as temporal arteritis, is a condition where large and medium-sized blood vessels, particularly those in the head, become inflamed. This can lead to symptoms such as headache, vision changes, jaw claudication, and scalp tenderness [2].

Actemra's Use in GCA Treatment

Actemra has been approved by the US FDA for the treatment of GCA, particularly for patients who are steroid-dependent or have a relapse. Actemra works by blocking the action of IL-6, a cytokine that contributes to inflammation in the body.

Clinical Trials and Data

Clinical trials, such as the GiACTA trial, have demonstrated the efficacy of Actemra in treating GCA. Patients treated with Actemra showed improvement in symptoms and reduced the need for steroids compared to those receiving placebo [3].

Pricing and Availability

Actemra's pricing varies depending on the country and region. However, it is generally more expensive than traditional GCA treatments, such as glucocorticoids.

Patent Information

Actemra's patents are owned by Hoffman-La Roche Ltd. The patent expiration date for Actemra in the US is expected to be around 2028 [4], although the exact date may vary depending on any potential patent extensions or challenges.

Competitors and Alternatives

Other medications, such as tocilizumab and baricitinib, are being researched for their potential in treating GCA. These alternatives may offer a lower cost or different side effect profiles compared to Actemra.

References

[1] Roche. (2022). Actemra (Tocilizumab). Retrieved from https://www.roche.com/product/actemra- tocilizumab.html

[2] National Institute of Neurological Disorders and Stroke. (2022). Giant Cell Arteritis Fact Sheet. Retrieved from https://www.ninds.nih.gov/Disorders/Patient-Education/Giant-Cell-Arteritis-Fact-Sheet

[3] Hoffman-La Roche Ltd. (2017). GiACTA: A Randomised Double-Blinded Double-Control Trial Comparing the Efficacy and Safety of Tocilizumab vs. Adalimumab in Patients with Giant Cell Arteritis. ClinicalTrials.gov Identifier: NCT02452348.

[4] DrugPatentWatch.com. (2023). Actemra patent information. Retrieved from https://www.drugpatentwatch.com/drug/actemra